Adenomatoid tumor should be considered in the differential diagnosis for testicular lesions in patients with cryptorchidism
Testicular Adenomatoid Tumor Linked to History of Cryptorchidism
This case report and literature review describes a 58-year-old man with cryptorchidism, male breast cancer, and thymic B2 thymoma who presen…
A new case report highlights a link between undescended testes and certain benign testicular tumors, helping doctors better identify similar…
Adherence to 2021 ABS imaging recommendations in 148 male breast referrals at a UK hospital
Why Most Lumps in Men Don't Need a Mammogram, but Many Still Get One
This retrospective observational cohort study evaluated adherence to 2021 ABS imaging recommendations among 148 male patients referred to a …
A year-long UK clinic review found that most men referred for breast lumps had benign conditions, yet imaging was often done despite nationa…
Research across Hormone Receptor-Positive Breast Cancer
Related studies from across the Hormone Receptor-Positive Breast Cancer family.
ICIs Boost pCR in Early Triple-Negative Breast Cancer
Immune drugs combined with chemotherapy improve results for triple-negative breast cancer
Adding immune checkpoint inhibitors to chemotherapy improves pathological complete response in early triple-negative breast cancer, with PD-…
Adding immune checkpoint inhibitors to chemotherapy significantly increases the chance of clearing cancer cells in triple-negative breast ca…
Platinum agents, PARP inhibitors, and immune checkpoint inhibitors increase pCR rates in early-stage TNBC
New data shows specific drug combinations improve triple-negative breast cancer outcomes
This network meta-analysis of 7,683 patients with early-stage triple-negative breast cancer (TNBC) evaluated various neoadjuvant treatment r…
New data shows that adding specific drugs like pembrolizumab or bevacizumab to standard chemotherapy can improve response rates for early-st…
Targeted therapy plus chemotherapy improves objective response and disease control rates in advanced TNBC
Targeted therapy plus chemotherapy improves response in triple-negative breast cancer
This systematic review and meta-analysis of 523 patients found that adding targeted therapy to chemotherapy for advanced triple-negative bre…
Adding targeted therapy to chemotherapy may improve how tumors respond in patients with advanced triple-negative breast cancer.
Adjuvant CDK4/6 inhibitors improve invasive Disease-Free Survival regardless of patient menopausal status
CDK4/6 inhibitors show consistent results for both pre and postmenopausal women
This meta-analysis of 17,748 patients with HR+ and HER2-negative early breast cancer found that adjuvant CDK4/6 inhibitors improved invasive…
New data suggests that a specific type of breast cancer treatment works effectively regardless of whether a patient has reached menopause.
Neoadjuvant immune checkpoint inhibitors plus chemotherapy increase pathological complete response in early-stage triple-negative breast cancer
Immune checkpoint inhibitors improve response in triple-negative breast cancer
This meta-analysis of 3,377 patients found that neoadjuvant immune checkpoint inhibitors combined with chemotherapy significantly increased …
Adding immune checkpoint inhibitors to chemotherapy helps more patients with early-stage triple-negative breast cancer achieve a complete re…
Chemokine networks regulate triple-negative breast cancer tumor microenvironment but clinical translation remains limited
Chemokine Targets Show Promise in Lab but Face Clinical Hurdles
This systematic review examines the role of chemokine networks and targeted interventions in the triple-negative breast cancer immune microe…
New research highlights the role of chemokine networks in breast cancer, showing strong results in labs despite challenges in current clinic…
Datopotamab deruxtecan improves progression-free survival to 10.8 months versus 5.6 months in TNBC
Trial shows datopotamab deruxtecan improves survival in triple-negative breast cancer
This Phase III randomized controlled trial of 644 patients with untreated, locally recurrent inoperable or metastatic triple-negative breast…
A new trial shows that datopotamab deruxtecan may extend progression-free and overall survival for patients with advanced triple-negative br…
Immune checkpoint inhibitors plus chemotherapy improve overall survival in advanced triple-negative breast cancer
Immunotherapy plus chemo improves survival in triple-negative breast cancer
This umbrella meta-analysis of 39,147 patients found that combining immune checkpoint inhibitors with chemotherapy significantly improves ov…
Adding immunotherapy to chemo helps some patients with advanced triple-negative breast cancer live longer, but side effects are more common.
Multimodal fusion and radiogenomic frameworks show promise for capturing heterogeneity in triple-negative breast cancer
Artificial Intelligence Shows Promise in Triple-Negative Breast Cancer Care
This narrative synthesis reviews the application of artificial intelligence across radiology, digital pathology, and multi-omics for triple-…
New research shows how artificial intelligence can help identify cancer subtypes and predict treatment responses for patients with triple-ne…
Small intestinal metastasis from triple-negative breast cancer can mimic lymphoma on imaging
Case report: Breast cancer spread to small intestine mimics lymphoma
This case report with literature review describes a patient with triple-negative breast cancer who developed small intestinal metastasis pre…
A breast cancer survivor's anemia was caused by a rare small intestine metastasis that looked like lymphoma on scans.
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
Chemo-immunotherapy yields 12-month disease-free status in rare triple-negative neuroendocrine breast cancer
A single patient remains disease-free after a new chemo-immunotherapy approach for rare breast cancer
This case report describes a 71-year-old woman with triple-negative neuroendocrine breast cancer treated with paclitaxel, cisplatin, and pem…
A 71-year-old woman with rare breast cancer stayed disease-free for a year using a combination of chemotherapy and immunotherapy that doctor…